{"result": "(\"entity\"<|>GH<|>ORGANIZATION<|>Growth hormone (GH) is a hormone that stimulates growth and is involved in the pathophysiology of acromegalia.)\n##\n(\"entity\"<|>ADENOMA HIPOFISARIO SOMATOTROPO<|>GEO<|>A somatotropin pituitary adenoma is a tumor that secretes growth hormone, commonly associated with acromegalia.)\n##\n(\"entity\"<|>CABERGOLINA<|>ORGANIZATION<|>Cabergoline is a dopamine agonist considered for use in patients with slightly elevated IGF-1 levels in the context of acromegalia treatment.)\n##\n(\"entity\"<|>HORMONAS<|>ORGANIZATION<|>Hormones are regulatory substances that control various physiological processes, including growth hormone in acromegalia.)\n##\n(\"relationship\"<|>ACROMEGALIA<|>GH<|>Growth hormone is a key factor in the development and treatment of acromegalia.<|>9)\n##\n(\"relationship\"<|>ACROMEGALIA<|>ADENOMA HIPOFISARIO SOMATOTROPO<|>Acromegalia is often caused by a somatotropin pituitary adenoma that secretes excess growth hormone.<|>9)\n##\n(\"relationship\"<|>ACROMEGALIA<|>CABERGOLINA<|>Cabergoline may be used as a treatment option for patients with acromegalia who have elevated IGF-1 levels.<|>6)\n##\n(\"relationship\"<|>ACROMEGALIA<|>HORMONAS<|>Hormones, particularly growth hormone, play a significant role in the pathophysiology of acromegalia.<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: GH son moderados, se preferirían o bien los análogos de la somatostatina o el pegvisomant:\n       48    Con respecto al tratamiento farmacológico de la acromegalia, señale la opción                                                                 •  Los análogos de la somatostatina se suelen utilizar de inicio, puesto que además de redu-\n             falsa:                                                                                                                                           cir la secreción de GH tienen un efecto antitumoral y pueden lograr reducción del tamaño\n                                                                                                                                                              del adenoma.\n             A. En respondedores parciales con análogos de somatostatina de primera generación                                                             •  El pegvisomant, al       no inhibir la    secreción de      GH, se asocia con aumento de las              cifras\n                 se recomienda incrementar la dosis o la frecuencia de administración.                                                                        de GH y el adenoma somatotropo puede seguir creciendo, aunque en la práctica clínica\n             B. El empleo de cabergolina como terapia de primera línea se contempla en pacientes                                                              esto es poco frecuente. Por tanto, el pegvisomant no sería la opción de primera línea en\n                 con niveles de IGF-1 ligeramente elevados.                                                                                                   pacientes con riesgo de crecimiento tumoral (opción C falsa) y lo indicado sería probar\n             C. En pacientes no controlados con terapia farmacológica de primera línea, con riesgo                                                            un análogo de somatostatina.\n                 de crecimiento tumoral, se recomienda el empleo de pegvisomant en monoterapia.                                                            Referencias:\n             D.  La pasireótida es un análogo de somatostatina de segunda generación que puede                                                             • Melmed S, Katznelson L. Treatment of acromegaly. En: Snyder PJ, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc.\n                                                                                                                                                             https://www.uptodate.com (acceso 29 de abril de 2019).\n                 deteriorar el control glucémico.\n\n\n\n             COMENTARIO                                                                                                                                49  En relación con la acromegalia, señale la afirmación falsa:\n             El tratamiento médico de la acromegalia está indicado:                                                                                        A. Los adenomas escasamente granulados suelen aparecer en pacientes más jóvenes\n                                                                                                                                                               que los densamente granulados.\n               •  Tras el fracaso de la cirugía para lograr el control bioquímico de la enfermedad.                                                        B. En la acromegalia, el patrón pulsátil de secreción de GH suele estar abolido.\n               •  Como tratamiento primario en pacientes con elevado riesgo quirúrgico, con negativa                                                       C. La normalización de la concentración de GH e IGF-1 tras el tratamiento está asociada\n                  a operarse o con baja probabilidad de curación con cirugía.                                                                                  con disminución de la morbimortalidad relacionada con la enfermedad.\n             Existen varias opciones de tratamiento médico disponibles, algunas destinadas a inhibir la                                                    D.  Los niveles elevados de IGF-1 están relacionados con la severidad de los cambios clínicos.\n             secreción de GH (análogos de somatostatina o agonistas dopaminérgicos) y otras a inhibir\n             su acción (pegvisomant).                                                                                                                      COMENTARIO\n             Análogos de somatostatina. Inhiben de forma más potente y duradera la secreción de GH que\n             la somatostatina nativa. Su eficacia se evaluaría con la normalización de la GH e IGF-1 séricas,                                              La acromegalia es una enfermedad crónica causada por una hipersecreción de GH, que es-\n             así como con la mejoría de la clínica de la acromegalia y la disminución del tamaño tumoral.                                                  timula a su vez la secreción de IGF-1, asociando crecimiento somático, múltiples comorbili-\n             Cuando existe una respuesta parcial a los análogos, que no logra el control bioquímico de la                                                  dades y mortalidad prematura. La elevación de los niveles de IGF-1 está relacionada con la\n             enfermedad, se puede aumentar la dosis de estos fármacos o acortar el intervalo de adminis-                                                   severidad de la clínica (respuesta D), pero la normalización de GH e IGF-1 con el tratamiento\n             tración (respuesta A).                                                                                                                        puede reducir el riesgo de mortalidad y mejorar las comorbilidades (respuesta C).\n             Si estamos empleando análogos de primera generación (octreotida, lanreótida) y no conse-                                                      Causas de acromegalia:\n             guimos controlar la enfermedad, otra opción sería probar un análogo de segunda generación\n             (pasireótida). El principal efecto adverso de este fármaco es su efecto negativo en el metabo-                                                •  En el 95% de los casos, la acromegalia se asocia a un adenoma hipofisario somatotropo,\n             lismo glucémico (es causa de aparición o empeoramiento de la hiperg\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ACROMEGALIA<|>EVENT<|>Acromegalia is a chronic disease caused by the hypersecretion of growth hormone (GH), leading to somatic growth and multiple comorbidities.)\n##\n(\"entity\"<|>SOMATOSTATINA<|>ORGANIZATION<|>Somatostatin is a hormone that inhibits the secretion of growth hormone and is used in treatment for acromegalia.)\n##\n(\"entity\"<|>PEGVISOMANT<|>ORGANIZATION<|>Pegvisomant is a medication used to treat acromegalia by inhibiting the action of growth hormone.)\n##\n(\"entity\"<|>OCTREOTIDA<|>ORGANIZATION<|>Octreotide is a first-generation somatostatin analogue used to control acromegalia.)\n##\n(\"entity\"<|>LANREOTIDA<|>ORGANIZATION<|>Lanreotide is another first-generation somatostatin analogue used in the treatment of acromegalia.)\n##\n(\"entity\"<|>PASIREOTIDA<|>ORGANIZATION<|>Pasireotide is a second-generation somatostatin analogue that may be used when first-generation analogues are ineffective.)\n##\n(\"entity\"<|>IGF-1<|>ORGANIZATION<|>Insulin-like growth factor 1 (IGF-1) is a hormone associated with the effects of growth hormone and is used to evaluate treatment efficacy in acromegalia.)\n##\n(\"entity\"<|>MORBIMORTALIDAD<|>EVENT<|>Morbimortalidad refers to the morbidity and mortality associated with acromegalia, which can be reduced with effective treatment.)\n##\n(\"relationship\"<|>ACROMEGALIA<|>SOMATOSTATINA<|>Somatostatin is used to inhibit the secretion of growth hormone, which is relevant in the treatment of acromegalia.<|>8)\n##\n(\"relationship\"<|>ACROMEGALIA<|>PEGVISOMANT<|>Pegvisomant is used to treat acromegalia by inhibiting the action of growth hormone.<|>8)\n##\n(\"relationship\"<|>ACROMEGALIA<|>OCTREOTIDA<|>Octreotide is a first-line treatment for controlling acromegalia.<|>8)\n##\n(\"relationship\"<|>ACROMEGALIA<|>LANREOTIDA<|>Lanreotide is also a first-line treatment for controlling acromegalia.<|>8)\n##\n(\"relationship\"<|>ACROMEGALIA<|>PASIREOTIDA<|>Pasireotide is used when first-generation somatostatin analogues fail to control acromegalia.<|>7)\n##\n(\"relationship\"<|>ACROMEGALIA<|>IGF-1<|>IGF-1 levels are used to evaluate the effectiveness of treatments for acromegalia.<|>9)\n##\n(\"relationship\"<|>ACROMEGALIA<|>MORBIMORTALIDAD<|>Effective treatment of acromegalia can reduce morbidity and mortality associated with the disease.<|>9)\n<|COMPLETE|>"}]}